Tigermed Receives MSCI ESG AAA Rating
Rhea-AI Summary
Tigermed (HNGZY) has achieved the highest possible MSCI ESG Rating of AAA, marking significant progress from its AA rating in 2023. The company has demonstrated excellence across environmental, social, and governance metrics.
Key achievements include validated science-based emissions reduction targets, investment of 39.997 million yuan in employee training with 99.48 average training hours per employee in 2024, and comprehensive ESG governance framework implementation. The company maintains 100% coverage of business ethics training for employees and requires suppliers to adhere to a strict Code of Conduct.
Positive
- Achieved highest possible MSCI ESG Rating (AAA), upgraded from AA in 2023
- Invested 39.997 million yuan in employee training with 99.48 hours per employee average
- Implemented comprehensive ESG governance framework with direct board oversight
- Maintains 100% coverage of business ethics training for all employees
Negative
- None.
MSCI's AAA rating is reserved for companies that demonstrate superior ESG performance and strong resilience to long-term risks. It reflects Tigermed's consistent efforts to integrate ESG principles into our core operations and strategic decision-making.
Environmental:
Tigermed has set science-based targets for reducing greenhouse gas emissions, which have been validated by the Science Based Targets initiative (SBTi). The company has implemented a comprehensive environmental management system, improved monitoring of emissions and resource utilization, and adopted digital platforms and green office initiatives to promote environmental sustainability.
Social:
W has advanced its digital transformation and leveraged AI technologies to enhance clinical trial efficiency. In 2024, Tigermed invested
Corporate Governance:
Tigermed has strengthened its ESG governance and compliance framework. The board of directors oversees all ESG-related matters, and the Compliance and ESG Committee is directly led by the General Manager and managed by the Chief Compliance Officer. ESG performance is incorporated into the General Manager's compensation structure. All employees receive
Since receiving its first MSCI ESG rating in 2020, Tigermed has consistently improved its performance, moving from a baseline rating to AA in 2023 and now achieving AAA. This progress reflects our ongoing investment in talent development, safety and quality management, carbon reduction, and ethical business practices.
This AAA rating marks a new milestone in our ESG journey. We will continue to strengthen our ESG governance framework, refine our management systems, and drive sustainable growth. As a company committed to "Serving Innovation, Building Health Together," we aim to deliver long-term value to our stakeholders while contributing to global health and well-being.
About Tigermed
Tigermed (Stock code: 300347.SZ/3347.HK) is a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry. With a broad portfolio of services and a promise of quality, from preclinical development to clinical trial to commercialization, we are collaborating with over 3,600 customers and committed to moving their development journey efficiently and cost-effectively. Tigermed currently represents a worldwide network of more than 180 locations with over 10,000 employees across
Learn more at www.tigermedgrp.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/tigermed-receives-msci-esg-aaa-rating-302532966.html
SOURCE Tigermed

